Adagene logo
Adagene
ADAG | NASDAQ
Chart Builder DCF Calculator
$1.60
-$0.11 (-6.43%)
At close: Nov 16, 2026, 4:00 PM ET
$1.60
$0.00 (0.00%)
After-hours: Nov 16, 2026, 7:30 PM ET

Adagene Company Profile

Company profile explained

Company Profile

Adagene Inc. functions as a clinical-stage biopharmaceutical organization, primarily concentrating on the identification, evolution, and fabrication of monoclonal antibody-based therapeutics engineered to combat various types of cancer. The company's developmental pipeline encompasses several investigational assets currently undergoing human trials. Among these is ADG106, a human ligand-blocking agonistic anti-CD137 monoclonal antibody, which is navigating Phase 1b/2 clinical assessment for individuals with advanced solid tumors and non-Hodgkin's lymphoma. Additionally, Adagene is progressing ADG126, a fully-human anti-CTLA-4 mAb, and ADG116, another human ligand-blocking anti-CTLA-4 mAb, both of which are advancing through Phase 1 studies for the treatment of advanced or metastatic solid tumors. Further along, ADG104, an anti-PD-L1 mAb, is in Phase 2 clinical development, and the innovative anti-CSF-1R mAb, ADG125, is undergoing Phase 1 trials. Beyond its clinical-stage programs, the firm also maintains an active preclinical portfolio. This includes ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is being explored for hematologic and solid tumor indications; ADG138, a novel HER2xCD3 POWERbody designed to target HER2-expressing solid tumors; and ADG152, a CD20xCD3 POWERbody under investigation for its potential to minimize off-tumor toxicities. Adagene Inc. was founded in 2011 and its principal operations are based in Suzhou, China.

Key Executives

Name Position
Peter Luo Co- Founder, Chairman, Chief Executive Officer and President of R&D
Man Kin Tam Chief Financial Officer & Director
Alexander Goergen Vice President & Head of Business Development
Chunfang Gu Executive Director of Finance
Guizhong Liu Senior Vice President of Early Drug Discovery
Jiping Zha Executive Vice President of Clinical Development
Ling Zhou Executive Director & Head of Human Resources
Mickael Chane-Du Chief Strategy Officer
Qinghai Zhao Chief Manufacturing Officer
Xiaohong She Senior Vice President & Head of Clinical Operations
Yan Li Senior Vice President of Bioinformatics & Information Technology

Latest SEC Filings

Date Type Title
Oct 02, 2026 4 Filing
Sep 25, 2026 4 Filing
Sep 25, 2026 6-K Filing
Sep 22, 2026 6-K Filing
Sep 17, 2026 4 Filing
Sep 10, 2026 6-K Filing
Sep 09, 2026 6-K Filing
Aug 18, 2026 4 Filing
Aug 17, 2026 4 Filing
Aug 17, 2026 4 Filing
View All SEC Filings ➞
Adagene
Adagene logo
Country China
IPO Date Feb 9, 2021
Industry Biotechnology
Sector Healthcare
Employees 128
CEO Peter Luo

Contact Details

Building C14 Suzhou, JS 215123 China

Stock Details

Ticker Symbol ADAG
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001818838
CUSIP Number 005329107
ISIN Number US0053291078
SIC Code 2834

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.